What is the current valuation of the US avascular necrosis market?

The market valuation was $120.0 Million in 2024. Read More

What is the projected market valuation for the US avascular necrosis market by 2035?

The projected valuation for 2035 is $230.0 Million. Read More

What is the expected CAGR for the US avascular necrosis market during the forecast period 2025 - 2035?

The expected CAGR is 6.09% during the forecast period 2025 - 2035. Read More

Which companies are the key players in the US avascular necrosis market?

Key players include Amgen Inc, Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc, Sanofi S.A., Eli Lilly and Company, Merck & Co., Inc., and AstraZeneca PLC. Read More

What are the main segments of the US avascular necrosis market?

The main segments include Type, Treatment, Diagnosis, and End User. Read More

What was the valuation for trauma-related avascular necrosis in 2024?

The valuation for trauma-related avascular necrosis was between $60.0 Million and $115.0 Million. Read More

What is the projected valuation for non-trauma related avascular necrosis by 2035?

The projected valuation for non-trauma related avascular necrosis is expected to reach between $60.0 Million and $115.0 Million. Read More

Which treatment segment had the highest valuation in 2024?

Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) had the highest valuation, ranging from $30.0 Million to $60.0 Million. Read More

What is the expected growth in the online pharmacy segment for avascular necrosis treatments?

The online pharmacy segment is projected to have a valuation between $30.0 Million and $50.0 Million. Read More

What diagnostic method had the highest valuation in 2024 for avascular necrosis?

Imaging had the highest valuation, ranging from $30.0 Million to $60.0 Million. Read More

US Avascular Necrosis Market

ID: MRFR/MED/11470-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

US Avascular Necrosis Market Research Report: By Type (Trauma Related Avascular Necrosis, Non-Trauma Related Avascular Necrosis), By Treatment (Nonsteroidal Anti-Inflammatory Drugs, Cholesterol Lowing Drugs, Osteoporosis Drugs, Blood Thinners, Others), By Diagnosis (Imaging, Biopsy, CT Scan, PET, X-Ray) and By End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Growth & Industry Forecast 2025 To 2035

US Avascular Necrosis Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Type (USD Million)
  1. 4.1.1 Trauma Related Avascular Necrosis (AVN)
  2. 4.1.2 Non-Trauma Related Avascular Necrosis (AVN)
2. 4.2 Food, Beverages & Nutrition, BY Treatment (USD Million)
  1. 4.2.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
  2. 4.2.2 Cholesterol Lowing Drugs
  3. 4.2.3 Osteoporosis Drugs
  4. 4.2.4 Blood Thinners
  5. 4.2.5 Others
3. 4.3 Food, Beverages & Nutrition, BY Diagnosis (USD Million)
  1. 4.3.1 Imaging
  2. 4.3.2 Biopsy
  3. 4.3.3 CT Scan
  4. 4.3.4 PET
  5. 4.3.5 X-Ray
4. 4.4 Food, Beverages & Nutrition, BY End User (USD Million)
  1. 4.4.1 Hospital Pharmacies
  2. 4.4.2 Retail Pharmacies
  3. 4.4.3 Online Pharmacies
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Amgen Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb Company (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Novartis AG (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Pfizer Inc (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sanofi S.A. (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Eli Lilly and Company (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Merck & Co., Inc. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AstraZeneca PLC (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY TREATMENT
4. 6.4 US MARKET ANALYSIS BY DIAGNOSIS
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
12. 6.12 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
13. 6.13 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 (% SHARE)
15. 6.15 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 TO 2035 (USD Million)
16. 6.16 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS, 2024 (% SHARE)
17. 6.17 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
18. 6.18 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 (% SHARE)
19. 6.19 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY DIAGNOSIS, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Type (USD Million, 2025-2035)

Trauma Related Avascular Necrosis (AVN)
Non-Trauma Related Avascular Necrosis (AVN)

Food, Beverages & Nutrition By Treatment (USD Million, 2025-2035)

Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
Cholesterol Lowing Drugs
Osteoporosis Drugs
Blood Thinners
Others

Food, Beverages & Nutrition By Diagnosis (USD Million, 2025-2035)

Imaging
Biopsy
CT Scan
PET
X-Ray

Food, Beverages & Nutrition By End User (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”